🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Abeona Therapeutics director sells $116,763 in company stock

Published 06/20/2024, 04:32 PM

A recent filing with the Securities and Exchange Commission revealed that Mark Alvino, a director of Abeona Therapeutics Inc. (NASDAQ:ABEO), sold a total of 25,890 shares of the company's common stock. The transactions took place on June 18, 2024, and were executed at a weighted average price of $4.51 per share, with the sale amount totaling approximately $116,763.

According to the SEC filing, the shares were sold in multiple transactions at prices ranging from $4.47 to $4.55. The sales were reportedly conducted to cover tax obligations associated with the vesting of restricted stock awards. Following the sale, Alvino's direct ownership in Abeona Therapeutics stands at 36,926 shares.

Abeona Therapeutics, based in Cleveland, Ohio, operates in the pharmaceutical industry, focusing on the development of therapies for life-threatening rare genetic diseases. The company's stock is publicly traded on the NASDAQ exchange under the ticker symbol ABEO.

Investors and stakeholders in Abeona Therapeutics often monitor insider transactions as they can provide insights into the company's financial health and the confidence level of its executives and directors in the firm's prospects. The recent transaction by Alvino may draw attention from the investment community as they assess its implications.

The SEC filing provides a detailed account of the transaction, including the commitment by Alvino to furnish further information about the number of shares sold at each price point within the specified range upon request. This transparency is part of the regulatory requirements for insider transactions to ensure fair disclosure to all market participants.

In other recent news, Abeona Therapeutics has been making significant strides in its operations. Stifel, a financial services company, has initiated coverage on shares of Abeona Therapeutics, assigning a 'buy' rating and setting a price target of $21. This optimism is rooted in the potential of Abeona's therapy, Prademagene zamikeracel (pz-cel), for treating recessive dystrophic epidermolysis bullosa (RDEB).

Furthermore, Abeona Therapeutics has announced an underwritten public offering of over 18 million shares and pre-funded warrants, expecting to raise approximately $75 million. The funds will be allocated to fund preparations for the resubmission of its Biologics License Application (BLA), commercialization efforts for pz-cel, and general corporate purposes.

On the regulatory front, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Abeona's BLA for pz-cel. The FDA requests additional Chemistry Manufacturing and Controls (CMC) information and Abeona plans to resubmit the BLA in the third quarter of 2024. These developments highlight the ongoing progress and challenges Abeona Therapeutics faces in its pursuit of advancing its novel treatment.

InvestingPro Insights

In light of the recent insider selling by Mark Alvino, a director at Abeona Therapeutics Inc. (NASDAQ:ABEO), investors may be looking for additional data points to gauge the company's current financial state and future prospects. The following insights from InvestingPro can provide a deeper understanding of Abeona's performance and valuation metrics:

Abeona Therapeutics has a market capitalization of approximately $185.15 million, reflecting the market's valuation of the company. Despite a significant revenue growth of 227.72% in the last twelve months as of Q1 2024, Abeona's financials show a substantial negative gross profit margin of -810.34% for the same period. This indicates that the cost of goods sold far exceeds the company's revenue, which is a concerning sign for profitability.

The stock's performance has been notably volatile, with a 39.71% decline over the past three months. InvestingPro Tips highlight that Abeona is not expected to be profitable this year, and analysts are keeping a close eye on the company's cash burn rate. On the positive side, Abeona holds more cash than debt on its balance sheet and has liquid assets that exceed its short-term obligations, which could provide some financial flexibility in the near term.

For investors seeking additional insights and analysis on Abeona Therapeutics, there are 9 more InvestingPro Tips available at https://www.investing.com/pro/ABEO. These tips can offer valuable guidance on the company's stock performance and financial health. Additionally, users can take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to a comprehensive set of investment tools and data.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.